skip to main content
Show Results with:

9 results  for Everything in this catalogue

Refined by: publisher: Elsevier Science remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Material Type:
Article
Add to My workspace

Revisiting RECIST: the case of treatment beyond progression

Daud, Adil I

The Lancet oncology. Volume 19:Issue 2 (2018); pp 157-159 -- Elsevier Science

Online access

2
Material Type:
Article
Add to My workspace

Negative but not futile: MAGE-A3 immunotherapeutic for melanoma

Daud, Adil I

The Lancet oncology. Volume 19:Number 7 (2018, July); pp 852-853 -- Elsevier Science

Online access

3
Material Type:
Article
Add to My workspace

Revisiting RECIST: the case of treatment beyond progression

Daud, Adil I

The Lancet oncology. Volume 19:Number 2 (2018, February); pp 157-159 -- Elsevier Science

Online access

4
Material Type:
Article
Add to My workspace

Negative but not futile: MAGE-A3 immunotherapeutic for melanoma

Daud, Adil I

The Lancet oncology. Volume 19:Issue 7 (2018); pp 852-853 -- Elsevier Science

Online access

5
Material Type:
Article
Add to My workspace

Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

Robert, Caroline et al.

The Lancet oncology. Volume 20:Number 9 (2019, September); pp 1239-1251 -- Elsevier Science

Online access

6
Material Type:
Article
Add to My workspace

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Amaria, Rodabe N et al.

The Lancet oncology. Volume 20:Number 7 (2019, July); pp e378-e389 -- Elsevier Science

Online access

7
Material Type:
Article
Add to My workspace

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Ribas, Antoni et al.

The Lancet oncology. Volume 16:Issue 8 (2015, August); pp 908-918 -- Elsevier Science

Online access

8
Material Type:
Article
Add to My workspace

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Ribas, Antoni et al.

The Lancet oncology. Volume 16:Issue 8 (2015, August); pp 908-918 -- Elsevier Science

Online access

9
Material Type:
Article
Add to My workspace

Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium

Andrews, Miles C et al.

The Lancet oncology. Volume 20:Issue 7 (2019); pp e378-e389 -- Elsevier Science

Online access

9 results  for Everything in this catalogue

Refine Search Results

Creation date 

From To

Additional Features 

  1. Abstract  (5)
  2. No Abstract  (4)
  3. Refine further open sub menu

Try a new search

Ignore my search and look for everything

by this Author/Contributor:

  1. Hamid, Omid
  2. Daud, Adil
  3. Blank, Christian U
  4. Robert, Caroline
  5. Kirkwood, John M.

Searching Remote Databases, Please Wait